Esperion Therapeutics Inc... (ESPR)
1.86
-0.04 (-2.11%)
At close: Feb 20, 2025, 3:59 PM
1.87
0.53%
After-hours: Feb 20, 2025, 05:09 PM EST
undefined% (undefined)
| Bid | 1.85 |
| Market Cap | 366.49M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.67 |
| PE Ratio (ttm) | -2.78 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.91 |
| Volume | 1,404,780 |
| Avg. Volume (20D) | 5,747,015 |
| Open | 1.91 |
| Previous Close | 1.90 |
| Day's Range | 1.85 - 1.93 |
| 52-Week Range | 1.58 - 3.94 |
| Beta | undefined |
About ESPR
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration a...
Sector Healthcare
IPO Date Jun 26, 2013
Employees 240
Stock Exchange NASDAQ
Ticker Symbol ESPR
Website https://www.esperion.com
Analyst Forecast
According to 6 analyst ratings, the average rating for ESPR stock is "Buy." The 12-month stock price forecast is $4, which is an increase of 115.05% from the latest price.
Buy 66.67%
Hold 16.67%
Sell 16.67%
Next Earnings Release
Esperion Therapeutics Inc. is scheduled to release its earnings on Mar 4, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
+5.58%
Esperion Therapeutics shares are trading higher af...
Unlock content with
Pro Subscription
2 months ago
+10.71%
Esperion Therapeutics shares are trading higher after the company announced it has filed a new drug submission to Health Canada for Nexletol and Nexlizet.
